Publication: LY.15
Published:Category: Publications
Reiman T, Savage KJ, Crump M, Cheung MC, MacDonald D, Buckstein R, Couban S, Piliotis E, Imrie K, Spaner D, Shivakumar S, Kuruvilla J, Villa D, Shepherd LE, Skamene T, Winch C, Chen BE, Hay AE. A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study (ONLINE). Leuk Lymphoma 1-8, 2018.
Read MoreCCTG Update: Protection Human Research Participant Training
Published:Category: Trials
The purpose of this memorandum is to provide an update on the Investigator requirement to complete Protection of Human Research Participant Training. As of September 26th 2018, the NIH Office of Extramural Research (OER) no longer offer the current free Protecting Human Research Participant (PHRP) training course and will not offer an alternative.
Read MoreTrial Activation: REC.4 (EA8143)
Published:Category: Trials
The CCTG trial REC.4 (EA8143), A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs.
Read MoreTrial Closure: PR.15
Published:Category: Trials
The PR.15 trial, a Randomized Phase II Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer has been permanently closed and no further ethics approvals or folow up data are required.
Read MoreTrial Closure: SRC.1
Published:Category: Trials
The CCTG SRC1 (ACOSOG Z9007) A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumors (GIST) has been permanently closed and no further ethics approvals or folow up data are required.
Read MoreOvarian Cancer prevention study explores the possibility of aspirin
Published:Category: News
Dr. Stephanie Lheureux discusses the CCTG OV.25 Ovarian Cancer Trial that explores the possibility of a prevention strategy for ovarian cancer. The OV.25 study targets woman who have the confirmed genetic mutation BRCA1 or BRCA2. Inflammation in the ovaries during ovulation is thought to contribute to the development of ovarian cancer and researchers want to understand if an anti-inflammatory intervention can help reduce the risk.
Read MoreClosed to accrual: CCTG SRC.6
Published:Category: Trials
The CCTG SRC.6 (COG ARST1321) study is now closed to accrual.
Thanks to the hard work of many across the CCTG group and collaborative working processes with our pediatric colleagues the SRC.6 trial met its primary endpoint early. Addition of pazopanib to preoperative chemoradiation increased rates of complete pathological response for individuals with sarcoma. Additional follow up is planned to determine if this translates into improved event free and overall survival. A huge thank you to everybody who contributed to this success.
Randomization of the first MA.39 patient!
Published:Category: Trials
MA.39 - Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
The randomization of the first MA.39 patient has been completed by the Juravinski Cancer Centre at Hamilton Health Sciences on October 16, 2018 - Congratulations! This site is lead by the Study Chair Tim Whelan and has four additional patients registered.